The health and wellness platform has acquired a NJ-based lab testing facility that will support its whole-body testing ambitions.
Athletech News has rounded up the top Super Bowl ads that are changing the conversation on health, wellness and female athleticism.
A new report from Hims & Hers underscores the urgency of weight loss for Americans as companies race to distribute weight loss medications.
Hims & Hers has added protein-packed meal replacement bars and shakes for GLP-1 users and those focused on weight management.
Hims & Hers has released a white paper showing that 87% of its GLP-1 weight loss program customers are close to their goal or have met it.
As GLP-1 drugs surge, here's how telehealth companies and brick-and-mortar fitness giants are responding to the Ozempic era.
JP Morgan Private Capital has raised over $500 million for a life sciences fund targeting private biotech companies and the booming weight-loss drug space.
Hims & Hers will now provide access to compounded GLP-1s for eligible consumers at a discounted rate compared to brand-name prescriptions.
Hims' new platform will roll out just in time for New Year’s resolutions, but will lean on generic medications instead of highly popular GLP-1s.
The new funding allows Define Ventures to continue its track record of investing in promising early-stage digital health startups.
Sign Up to Our Newsletter
